Instil Bio Inc(TIL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.47 | Insider Own | 38.58% | Shs Outstand | 6.8M | Perf Week | -1.18% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.2M | Perf Month | -17.98% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | - | Inst Own | 28.36% | Short Float | 3.81% | Perf Quarter | -18.32% |
| Income | -0.03B | P/S | - | EPS this Y | - | Inst Trans | 0.3% | Short Ratio | 8.38 | Perf Half Y | -27.5% |
| Sales | 0.00B | P/B | 0.37 | EPS next 5Y | - | ROA | -14.13% | Short Interest | 0.16M | Perf YTD | -46.91% |
| Book/sh | 15.83 | P/C | 0.57 | EPS past 3/5Y | 32.28% -12.7% | ROE | -25.33% | 52W High | -70.96% ($20.11) | Perf Year | -69.26% |
| Cash/sh | 10.31 | P/FCF | - | Sales past 3/5Y | - | ROIC | -15.58% | 52W Low | 3.91% ($5.62) | Perf 3Y | -20.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 65.39% | Gross Margin | - | Volatility(W/M) | 6.78% 5.13% | Perf 5Y | -98.4% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.34 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 21.67 | EPS Q/Q | 80.45% | Profit Margin | - | RSI (14) | 32.16 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.67 | Sales Q/Q | - | SMA20 | -9.95% ($6.49) | Beta | 1.95 | Target Price | $7 |
| Payout | - | Debt/Eq | 0.81 | Earnings | 2026/8/13 | SMA50 | -17.29% ($7.06) | Rel Volume | 6.4 | Prev Close | $5.7 |
| Employees | 17 | LT Debt/Eq | 0.81 | EPS/Sales Surpr. | -80% - | SMA200 | -24.19% ($7.7) | Avg Volume(3M) | 0.02M | Price | $5.84 |
| IPO | 2021/3/19 | Option/Short | No/Yes | Trades | 823 | Volume | 121,353 | Change | 2.46% |
A clinical-stage biotech company that was developing Tumor-Infiltrating Lymphocyte (TIL) therapy. The company is now at a strategic pivot point, having halted its existing pipeline and is seeking to acquire or in-license new therapeutic candidates, leveraging its strong cash position.
Over the past 1 year, on the lower side
71% below its 1-year high.
Traded more than usual. That is 640% of its average volume.
TIL has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
DFAC U.S. Core Equity 2 Portfolio-ETF Class Shares <0.01% 
DFAS U.S. Small Cap Portfolio-ETF Class Shares <0.01% 
AVSC Avantis U.S Small Cap Equity ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
VCIT Vanguard Intermediate-Term Corporate Bond ETF 67.3B 
VCSH Vanguard Short-Term Corporate Bond ETF 44.9B 
JPST JPMorgan Ultra-Short Income ETF 42.9B 
DYNF iShares U.S. Equity Factor Rotation Active ETF 42.2B 
USMV iShares MSCI USA Min Vol Factor ETF 24.3B It ranks #434 of 595 in the industry
Based on market cap of $40M.
FAQ
What kind of company is TIL?
TIL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TIL?
The market cap of TIL is approximately $40M, ranking 4,967 within its sector.
What is the 52-week high and low for TIL?
TIL has recorded a 52-week high of $20.11 and a low of $5.62.
